135 related articles for article (PubMed ID: 17934179)
1. Injury among stimulant-treated youth with ADHD.
Marcus SC; Wan GJ; Zhang HF; Olfson M
J Atten Disord; 2008 Jul; 12(1):64-9. PubMed ID: 17934179
[TBL] [Abstract][Full Text] [Related]
2. Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children.
Levin H; Hanten G; Max J; Li X; Swank P; Ewing-Cobbs L; Dennis M; Menefee DS; Schachar R
J Dev Behav Pediatr; 2007 Apr; 28(2):108-18. PubMed ID: 17435461
[TBL] [Abstract][Full Text] [Related]
3. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
4. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
8. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
Leibson CL; Barbaresi WJ; Ransom J; Colligan RC; Kemner J; Weaver AL; Katusic SK
Ambul Pediatr; 2006; 6(1):45-53. PubMed ID: 16443183
[TBL] [Abstract][Full Text] [Related]
9. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
10. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
11. Attention deficit hyperactivity disorder and increased risk of injury.
Merrill RM; Lyon JL; Baker RK; Gren LH
Adv Med Sci; 2009; 54(1):20-6. PubMed ID: 19586835
[TBL] [Abstract][Full Text] [Related]
12. Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?
Calver J; Sanfilippo F; Preen D; Bulsara M
Aust N Z J Public Health; 2007 Dec; 31(6):533-9. PubMed ID: 18081573
[TBL] [Abstract][Full Text] [Related]
13. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD.
Faraone SV; Biederman J; Zimmerman B
J Atten Disord; 2007 Sep; 11(2):157-66. PubMed ID: 17494833
[TBL] [Abstract][Full Text] [Related]
14. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Palli SR; Kamble PS; Chen H; Aparasu RR
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):139-48. PubMed ID: 22364400
[TBL] [Abstract][Full Text] [Related]
15. Trends in medication treatment for ADHD.
Castle L; Aubert RE; Verbrugge RR; Khalid M; Epstein RS
J Atten Disord; 2007 May; 10(4):335-42. PubMed ID: 17449832
[TBL] [Abstract][Full Text] [Related]
16. Identified attention-deficit/hyperactivity disorder and medically attended, nonfatal injuries: US school-age children, 1997-2002.
Pastor PN; Reuben CA
Ambul Pediatr; 2006; 6(1):38-44. PubMed ID: 16443182
[TBL] [Abstract][Full Text] [Related]
17. Child characteristics and receipt of stimulant medications: a population-based study.
Miller AR; Kohen D; Johnston C
Ambul Pediatr; 2008; 8(3):175-81. PubMed ID: 18501864
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
[TBL] [Abstract][Full Text] [Related]
19. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
Faraone SV; Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
[TBL] [Abstract][Full Text] [Related]
20. ADHD and the rise in stimulant use among children.
Mayes R; Bagwell C; Erkulwater J
Harv Rev Psychiatry; 2008; 16(3):151-66. PubMed ID: 18569037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
